Department of Pharmacy Practice, University of Rhode Island, Kingston, RI 02881, USA.
Mod Rheumatol. 2013 Jul;23(4):709-15. doi: 10.1007/s10165-012-0716-8. Epub 2012 Jul 13.
To determine the risk of severe infection requiring or complicating hospitalization associated with leflunomide therapy in patients with rheumatoid arthritis (RA).
We performed a retrospective study of RA patients who were prescribed leflunomide between 2004 and 2011. Background clinical and laboratory features were compared between patients who suffered severe leflunomide-associated infections and those who did not.
Since January 2005, 401 RA patients have started on leflunomide. Among those, 33 (8.2%) developed severe infections: pneumonia, oral candidiasis, pyelonephritis, pulmonary tuberculosis, cellulitis, disseminated herpes zoster, tonsillitis, and pulmonary cryptococcosis. Logistic regression showed that age at entry, the presence of DM, and daily dosage of corticosteroid were associated with development of severe infections.
These results showed that some patients with RA who were taking leflunomide developed severe infections requiring hospitalization, and that older age, DM, and a higher daily dosage of corticosteroid were risk factors associated with leflunomide-associated severe infections.
确定类风湿关节炎（RA）患者接受来氟米特治疗后发生严重感染需要住院或并发感染的风险。
我们对 2004 年至 2011 年间接受来氟米特治疗的 RA 患者进行了回顾性研究。比较了发生严重来氟米特相关感染的患者与未发生感染的患者的背景临床和实验室特征。
自 2005 年 1 月以来，已有 401 名 RA 患者开始服用来氟米特。其中 33 人（8.2%）发生严重感染：肺炎、口腔念珠菌病、肾盂肾炎、肺结核、蜂窝织炎、播散性带状疱疹、扁桃体炎和肺隐球菌病。Logistic 回归显示，进入时的年龄、DM 的存在和皮质类固醇的日剂量与严重感染的发生有关。
这些结果表明，一些服用来氟米特的 RA 患者发生了需要住院治疗的严重感染，且年龄较大、DM 以及更高的皮质类固醇日剂量是与来氟米特相关严重感染相关的危险因素。
